Business

Glenmark Pharmaarm submits IPO documents to Sebi

New Delhi, April 17 (PTI) Glenmark Pharmaceuticals said Saturday that its wholly owned division, Glenmark Life Sciences, had submitted an initial public offering reserve to market regulator Sebi. ..
Glenmark Life Sciences has submitted a Draft Red Herring Prospectus (DRHP) to the Securities and Exchange Commission of India (Sebi) for an initial public offering, according to a regulatory submission.
The offer consists of a new issue of up to Rs 1,160 by Glenmark Pharmaceuticals Ltd and an offer to sell up to 73,05,245 shares of Glenmark Life Sciences Ltd for up to Rs 2 each.
During the April 16 meeting, the board of directors of Glenmark Pharmaceuticals Ltd approved an offer to sell up to 73,05,245 shares of Rs per share as part of its IPO.
According to the filing, the IPO is subject to market conditions, receipt of applicable approvals and other considerations.

The story was taken from a news agency

get Latest business news, Stock market With updates videoCheck your tax spending Income tax calculator And save money through us Personal loan coverage.check Business breaking news live on Zee Business Twitter And Facebook..subscribe YouTube..

function loadshare(curl) { history.pushState('', '', curl); if (window.OBR) { window.OBR.extern.researchWidget(); } if (_up == false) { var cu_url = curl; ga('set', 'page', curl); ga('send', 'pageview'); } } if (use_ajax == false) { var view_selector="div#maincontent"; var content_selector = view_selector; var items_selector = content_selector + ' > div.repeat-block'; var pager_selector="div.view-zbiz-article-prev-next > div.view-content > div > div.next-article-blick-biz"; var next_selector="div.view-zbiz-article-prev-next > div.view-content > div > div.next-article-blick-biz > a:last"; var auto_selector="div.view-zbiz-article-prev-next"; var img_location = view_selector + ' > div.repeat-block:last'; var img_path=""; var img = '

'; var x = 0; var url=""; var prevLoc = window.location.pathname; var circle = ""; var myTimer = ""; var interval = 30; var angle = 0; var Inverval = ""; var angle_increment = 6; var handle = $.autopager({ appendTo: content_selector, content: items_selector, runscroll: maindiv, link: next_selector, autoLoad: false, page: 0, start: function () { $(img_location).after(img); }, load: function () { $('#views_infinite_scroll-ajax-loader').remove(); $('div#main-rhs' + x).empty(); //console.log($('div#main-rhs155135 > div.sidebar155135 > div:first').text()); $('#maincontent >.row:last').before('

'); $(rightside).clone().appendTo('div#main-rhs' + x); $(".sidebar" + x).theiaStickySidebar(); var fb_script = document.createElement('script'); fb_script.text = "(function(d, s, id) {var js, fjs = d.getElementsByTagName(s)[0];if (d.getElementById(id)) return;js = d.createElement(s); js.id = id;js.src="https://connect.facebook.net/en_GB/sdk.js#xfbml=1&version=v2.9";fjs.parentNode.insertBefore(js, fjs);}(document, 'script', 'facebook-jssdk'));"; var fmain = $(".sr" + x); var fdiv = '

'; $(fdiv).appendTo(fmain); FB.XFBML.parse(); var $dfpAd = $('#maincontent').children().find("#ad-" + x); var $dfpAdMob = $('#maincontent').children().find("#ad-mob-" + x); var $dfpAdrhs = $('#main-rhs' + x).children().find('.adATF').empty().attr("id", "ad-300-" + x); var $dfpAdrhs2 = $('#main-rhs' + x).children().find('.adBTF').empty().attr("id", "ad-300-2-" + x); $('body').children('.outpage').empty().append('

 

'); var $dfpAdOutofpage = $('body').children('div.opage'); var instagram_script = document.createElement('script'); instagram_script.defer="defer"; instagram_script.async="async"; instagram_script.src="https://platform.instagram.com/en_US/embeds.js"; setTimeout(function () { var twit = $("div.field-name-body").find('blockquote[class^="twitter"]').length; var insta = $("div.field-name-body").find('blockquote[class^="instagram"]').length; if (twit == 0) { twit = ($("div.field-name-body").find('twitterwidget[class^="twitter"]').length); } if (twit > 0) { if (typeof (twttr) != 'undefined') { twttr.widgets.load();

} else { $.getScript('//platform.twitter.com/widgets.js'); } } if (insta > 0) { $('#maincontent >.row:last').after(instagram_script); window.instgrm.Embeds.process(); } }, 1500); } });

$(document).delegate("button[id^='mf']", "click", function () { fbcontainer=""; fbid = '#' + $(this).attr('id'); var sr = fbid.replace("#mf", ".sr");

$(fbid).parent().children(sr).toggle(); fbcontainer = $(fbid).parent().children(sr).children(".fb-comments").attr("id"); });

var title, imageUrl, description, author, shortName, identifier, timestamp, summary, newsID, nextnews; var previousScroll = 0; $(window).scroll(function () { var last = $(auto_selector).filter(':last'); var lastHeight = last.offset().top; var currentScroll = $(this).scrollTop(); if (currentScroll > previousScroll) { _up = false; } else { _up = true; } previousScroll = currentScroll; var cutoff = $(window).scrollTop() + 64; $('div[id^="row"]').each(function () { if ($(this).offset().top + $(this).height() > cutoff) { if (prevLoc != $(this).children().find('.article-box').attr('data-url')) { prevLoc = $(this).children().find('.article-box').attr('data-url'); $('html head').find('title').text($(this).children().find('.article-box').attr('data-title')); loadshare(prevLoc); } return false; // stops the iteration after the first one on screen } }); if (lastHeight + last.height() < $(document).scrollTop() + $(window).height()) { url = $(next_selector).attr('href'); x = $(next_selector).attr('id'); } }); } } }); } }; })(jQuery);

Glenmark Pharmaarm submits IPO documents to Sebi

Source link Glenmark Pharmaarm submits IPO documents to Sebi

Related Articles

Back to top button